IL277474B2 - Methods for treating chronic spontaneous urticaria using liglizumab - Google Patents

Methods for treating chronic spontaneous urticaria using liglizumab

Info

Publication number
IL277474B2
IL277474B2 IL277474A IL27747420A IL277474B2 IL 277474 B2 IL277474 B2 IL 277474B2 IL 277474 A IL277474 A IL 277474A IL 27747420 A IL27747420 A IL 27747420A IL 277474 B2 IL277474 B2 IL 277474B2
Authority
IL
Israel
Prior art keywords
ligelizumab
methods
treating chronic
chronic spontaneous
spontaneous urticaria
Prior art date
Application number
IL277474A
Other languages
English (en)
Hebrew (he)
Other versions
IL277474B1 (en
IL277474A (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL277474A publication Critical patent/IL277474A/en
Publication of IL277474B1 publication Critical patent/IL277474B1/en
Publication of IL277474B2 publication Critical patent/IL277474B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dermatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
IL277474A 2018-03-26 2019-03-25 Methods for treating chronic spontaneous urticaria using liglizumab IL277474B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862647928P 2018-03-26 2018-03-26
US201962811800P 2019-02-28 2019-02-28
PCT/IB2019/052408 WO2019186369A1 (en) 2018-03-26 2019-03-25 Methods of treating chronic spontaneous urticaria using ligelizumab

Publications (3)

Publication Number Publication Date
IL277474A IL277474A (en) 2020-11-30
IL277474B1 IL277474B1 (en) 2025-12-01
IL277474B2 true IL277474B2 (en) 2026-04-01

Family

ID=66476672

Family Applications (1)

Application Number Title Priority Date Filing Date
IL277474A IL277474B2 (en) 2018-03-26 2019-03-25 Methods for treating chronic spontaneous urticaria using liglizumab

Country Status (9)

Country Link
US (2) US20210115155A1 (https=)
EP (1) EP3773904A1 (https=)
JP (1) JP7589045B2 (https=)
KR (1) KR20200135826A (https=)
CN (1) CN112203724A (https=)
AU (1) AU2019244666A1 (https=)
CA (1) CA3094749A1 (https=)
IL (1) IL277474B2 (https=)
WO (1) WO2019186369A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021250533A1 (en) * 2020-06-09 2021-12-16 Novartis Ag Methods of treatment using omalizumab or ligelizumab
WO2021250546A1 (en) 2020-06-09 2021-12-16 University Of Washington Micrornas as predictors of response to anti-ige therapies in chronic spontaneous urticaria
CA3220757A1 (en) * 2021-06-14 2022-12-22 Novartis Ag Pharmaceutical formulation containing an anti-ige antibody
EP4384553A1 (en) * 2021-08-13 2024-06-19 Genentech, Inc. Dosing for anti-tryptase antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2005075504A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. IDENTIFICATION OF NOVEL IgE EPITOPES

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0200429D0 (en) * 2002-01-09 2002-02-27 Novartis Ag Organic compounds
SI2000481T1 (sl) * 2003-02-01 2016-08-31 Tanox, Inc. Anti-humana protitelesa IgE z visoko afiniteto
US20130005708A1 (en) * 2011-06-29 2013-01-03 Lalwani Dinusha N Histamine antagonist treatment of inflammatory skin disorders
TW201343176A (zh) * 2012-04-16 2013-11-01 Novartis Ag 使用ｉｌ－１７拮抗劑治療乾癬性關節炎之方法
CN104547325A (zh) * 2015-01-21 2015-04-29 李健 一种治疗慢性特发性荨麻疹的药物组合物及其应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040197324A1 (en) * 2003-04-04 2004-10-07 Genentech, Inc. High concentration antibody and protein formulations
WO2005075504A1 (en) * 2004-02-02 2005-08-18 Tanox, Inc. IDENTIFICATION OF NOVEL IgE EPITOPES

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
NOVARTIS, DOSE-FINDING STUDY OF QGE031 AS ADD-ON THERAPY TO EVALUATE EFFICACY AND SAFETY IN PATIENTS WITH CSU, 22 June 2015 (2015-06-22) *
NOVARTIS,, STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF QGE031 IN ADOLESCENT PATIENTS WITH CHRONIC SPONTANEOUS URTICARIA (CSU), 19 February 2018 (2018-02-19) *
RAGIP ERTAS,, ANTI IGE THERAPY IN CHRONIC URTICARIA" , " A COMPREHENSIVE REVIEW OF URTICARIA AND ANGIOEDEMA, 31 May 2017 (2017-05-31) *

Also Published As

Publication number Publication date
JP2021523881A (ja) 2021-09-09
JP7589045B2 (ja) 2024-11-25
US20210115155A1 (en) 2021-04-22
KR20200135826A (ko) 2020-12-03
EP3773904A1 (en) 2021-02-17
US20250026858A1 (en) 2025-01-23
WO2019186369A1 (en) 2019-10-03
RU2020134794A (ru) 2022-04-26
IL277474B1 (en) 2025-12-01
IL277474A (en) 2020-11-30
CA3094749A1 (en) 2019-10-03
RU2020134794A3 (https=) 2022-04-26
AU2019244666A1 (en) 2020-10-08
CN112203724A (zh) 2021-01-08

Similar Documents

Publication Publication Date Title
IL285151B1 (en) Methods for the treatment of fgf21-related disorders
IL275663A (en) Cancer treatment methods
IL266770A (en) Methods for treating inflammatory conditions
SG11202010830WA (en) Methods of treating phenylketonuria
IL283337A (en) Methods for treating whsc1-overexpressing cancers by inhibiting setd2
ZA201903873B (en) Methods of treating cochlear synaptopathy
IL277474A (en) Methods for the treatment of chronic spontaneous urticaria using ligizumab
IL284797A (en) Addiction treatment methods
IL277981A (en) Cancer treatment methods
IL271934A (en) Methods for treating tumor metastases
SI3661510T1 (sl) Postopki zdravljenja vedenjskih sprememb
SG11202010793UA (en) Methods of treating cancer
IL287210A (en) Preparations for the treatment of tumors
IL274314A (en) Tumor treatment methods
IL281600B2 (en) Cancer treatment methods
IL261767A (en) Methods for treating or preventing graft-versus-host disease
SG11202010911WA (en) Methods and compositions for treating chronic urticaria
SG11202005163PA (en) Methods of treating cancer
SG11202102240YA (en) Methods of treating psoriasis
IL269123A (en) Methods of treating cancer
IL262916A (en) Treatment of side effects resulting from chemo-nervous disorder
IL273500A (en) Treatment methods for acute or chronic pain
HK40036558A (en) Methods of treating chronic spontaneous urticaria using ligelizumab
ZA201908495B (en) Methods of treating symptoms of gastroparesis using velusetrag
SG11202101817UA (en) Methods of inhibition